Market open
Allogene Therapeutics/$ALLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Ticker
$ALLO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
228
ISIN
US0197701065
Website
ALLO Metrics
BasicAdvanced
$208M
-
-$1.22
0.60
-
Price and volume
Market cap
$208M
Beta
0.6
52-week high
$3.78
52-week low
$0.86
Average daily volume
3.6M
Financial strength
Current ratio
9.712
Quick ratio
9.405
Long term debt to equity
21.093
Total debt to equity
23.073
Interest coverage (TTM)
-764.86%
Management effectiveness
Return on assets (TTM)
-28.92%
Return on equity (TTM)
-59.60%
Valuation
Price to book
0.54
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-0.992
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-31.79%
3-year earnings per share growth (CAGR)
-17.78%
What the Analysts think about ALLO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.
ALLO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ALLO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ALLO News
AllArticlesVideos
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
GlobeNewsWire·2 days ago
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Allogene Therapeutics stock?
Allogene Therapeutics (ALLO) has a market cap of $208M as of May 15, 2025.
What is the P/E ratio for Allogene Therapeutics stock?
The price to earnings (P/E) ratio for Allogene Therapeutics (ALLO) stock is 0 as of May 15, 2025.
Does Allogene Therapeutics stock pay dividends?
No, Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Allogene Therapeutics dividend payment date?
Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Allogene Therapeutics?
Allogene Therapeutics (ALLO) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.